Norway Archives

News and Trends 20 Apr 2017

Norway Brings Another Cancer Vaccine to the Clinic

Targovax has recruited its first patient in a Phase Ib trial for its new cancer vaccine TG02 targeting mutations of the RAS gene. Mutations of the RAS gene disrupt normal cell division and are a key driver of cancer progression and treatment resistance. The Norwegian biotech Targovax is developing peptide-based anti-cancer vaccines targeting these mutations found […]

April 20, 2017 - 3 minutesmins - By Melanie De Almeida

News and Trends 6 Apr 2017

UPDATE: Norwegian Stock Exchange hits Record Biotech IPO

UPDATE (06/04/2017): BerGenBio has raised €43.55M, successfully beating a biotech record on the Norwegian stock exchange and setting its market cap at €135M. UPDATE (28/03/2017): BerGenBio has announced that the IPO could run up to €44M on Oslo Børs. It could become the Norway stock exchange’s biggest IPO in biotech, and indeed €44M would make it […]

April 6, 2017 - 3 minutesmins - By Melanie De Almeida

News and Trends 7 Dec 2016

Investors bid on Nordic Nanovector’s Hottest Cancer Antibodies

Nordic Nanovector has bagged €55M to push its pipeline forward through the clinic. Investors seem to be attracted by its ARC and ADC programs, using some of the hottest antibody technologies to treat cancer. Nordic Nanovector develops antibody-radionuclide conjugates (ARCs) to treat non-Hodgkin lymphoma (NHL) and recently entered the trending antibody-drug conjugate (ADC) field to fight against leukemia. These […]

December 7, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

Screenshot 2016 11 17 at 5.37.49 PM e1479400708474

News and Trends 18 Nov 2016

Can Oncolytic Viruses be the key to Treat Resistant Tumors?

This week, we leave Belgium and keep traveling north to Oslo, where snow is starting to pack for the joy of skiers. Meanwhile, Targovax is there working hard to treat cancer with its immunotherapy pipeline. City: Oslo, Norway Founded: 2010 Employees: 20 – 30 Financial data: €12M raised in a private placement in July Mission: Targovax develops immuno-oncology […]

November 18, 2016 - 1 minutemin - By Clara Rodríguez Fernández

News and Trends 26 Oct 2016

Can this new Antibody-Drug Conjugate Collaboration make it to the Top?

Nordic Nanovector is collaborating with Heidelberg Pharma to access the promising antibody-drug conjugate (ADC) technology. However, can it really take on the strong competition? Nordic Nanovector develops antibody-radionuclide conjugates (ARCs) to treat Non-Hodgkin Lymphoma (NHL) and other blood cancers. Today, the company has announced a collaboration with Wilex’ subsidiary Heidelberg Pharma to incorporate antibody-drug conjugates (ADCs) […]

October 26, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 11 Jul 2016

On the way to a ‘Functional’ HIV Cure? Norway Vaccine clears viral load in 88% of Patients

Oslo based Biopharma Bionor has a Phase I results for a HIV vaccine. The vaccine infusion rendered viral presence in 88% of patients undetectable after combination treatments with Celgene‘s enzyme inhibitor, Istodax and standard retroviral drugs. The positive results from the clinical trial REDUC Part B were published in the high impact journal The Lancet HIV. The Norwegian’s proprietary […]

July 11, 2016 - 3 minutesmins - By Dani Bancroft

News and Trends 13 May 2016

Biotech of the Week: Avexxin, reducing inflammatory diseases from far up in Norway

We’re not going particularly far this week and we aren’t even leaving Scandinavia! From Stockholm, we are crossing the border to Norway and go up North. Sadly it’s not the see the Northern Lights but to visit Trondheim, where Avexxin, our Biotech of the Week is located. City: Trondheim (Norway) Founded: 2005 Employees: 8 (as of […]

May 13, 2016 - 1 minutemin - By Joachim Eeckhout

News and Trends 12 Feb 2016

Biotech of the week: Nordic Nanovector & its ARC technology

This week we say ‘au revoir’ to Nantes and head back up to the Scandinavian country that is Norway, in particular it’s capital city, Oslo – the location of our biotech of the week, Nordic Nanovector. City: Oslo, Norway Founded: 2009 Employees: +/- 30 (as off 11/15) Financial Data: €156M Market Cap (on 23/11/2015) CEO: Missions: Betalutin, a potential new treatment […]

February 12, 2016 - 1 minutemin - By Philip Hemme

glycomar astaxanthin polysacchiride prasinotech mmicroa microalgae biotech algae

News and Trends 14 Jan 2016

World First: Scotland and Norway have Founded a Unique Oceanic Algae Plant

GlycoMar (Scotland) and MicroA (Norway) are Algae specialists in the Biotech industry which have now funded a joint Venture, Prasinotech, which is the first in the world to refine the production of polysaccharides from microalgae. GlycoMar is based at the European Centre for Marine Biotechnology, near Oban (Scotland), and is a specialist biotech developing new […]

January 14, 2016 - 3 minutesmins - By Dani Bancroft

News and Trends 10 Nov 2015

The 10 Hottest Bioincubators in Europe

A Bioincubator is a launch-pad structure for entrepreneurs to make their project in the sciences real. In Europe, we have many incubators within each industry, responsible for strategic investment, development and providing a support network for start-ups. Bioincubators are considered as the first ‘home’ for young biotech companies, providing entrepreneurs access to research laboratories, technology platforms, specific […]

November 10, 2015 - 5 minutesmins - By Nicolas Sainte-Foie

News and Trends 12 Jun 2015

Polaris, a new Nordic leader in Immuno-Oncology

Immuno-oncology is a busy market to take on by yourself due to the existing fierce competition. Targovax and Oncos Therapeutics have decided to merge to earn a spot in the field. Polaris, the combined business, contemplates a private placement of around €15M to fund the freshly baked company. Finland and Norway never were this close as Oncos […]

June 12, 2015 - 2 minutesmins - By Lourdes Riquelme

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us